ketoconazole has been researched along with debrisoquin in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (20.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (40.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Atiba, JO; Blaschke, TF; Wilkinson, GR | 1 |
AL-Shurbaji, A; Annas, A; Dahl, ML; Lindh, JD; Meurling, L | 1 |
2 trial(s) available for ketoconazole and debrisoquin
Article | Year |
---|---|
Effects of ketoconazole on the polymorphic 4-hydroxylations of S-mephenytoin and debrisoquine.
Topics: Adult; Debrisoquin; Humans; Hydantoins; Hydroxylation; Isoquinolines; Ketoconazole; Male; Mephenytoin; Oxidation-Reduction; Phenotype; Stereoisomerism | 1989 |
Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine.
Topics: Administration, Oral; Adult; Antidepressive Agents, Second-Generation; Area Under Curve; Cyclohexanols; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Debrisoquin; Drug Interactions; Female; Genotype; Half-Life; Humans; Ketoconazole; Male; Middle Aged; Phenotype; Venlafaxine Hydrochloride; White People | 2003 |
3 other study(ies) available for ketoconazole and debrisoquin
Article | Year |
---|---|
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |